Hypothyroidism in patients treated with immune checkpoint inhibitors

Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune checkpoint inhibitors: A pan-cancer analysis

10.3390/cancers13236109 · doi-reference

Clinical features of nivolumab-induced thyroiditis: A case series study

10.1089/thy.2016.0562 · doi-reference

Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy

10.1371/journal.pone.0156925 · doi-reference

Levothyroxine interactions with food and dietary supplements: A systematic review

10.3390/ph14030206 · doi-reference

A decrease in peripheral thyroid hormone conversion efficiency in patients treated with immune checkpoint inhibitors and L-T3 as a possible alternative therapeutic escape option

10.1111/eci.13790 · doi-reference

CTLA-4: A moving target in immunotherapy

10.1182/blood-2017-06-741033 · doi-reference

The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC

10.1080/1750743x.2024.2394382 · doi-reference

Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization

10.1080/21645515.2024.2410557 · doi-reference

Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms

10.3389/fendo.2025.1584675 · doi-reference

Clinical significance of thyroid autoantibodies in differential diagnosis and predicting the course of programmed cell death protein-1 inhibitor-induced thyroid dysfunction

10.1016/j.eprac.2024.08.012 · doi-reference

PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients

10.1089/thy.2019.0250 · doi-reference

Immune-related thyroiditis with immune checkpoint inhibitors

10.1089/thy.2018.0116 · doi-reference

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline

10.1530/eje-22-0689 · doi-reference

Sex: A potential factor affecting immune checkpoint inhibitor therapy for cancers

10.3389/fimmu.2022.1024112 · doi-reference

Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2022.10.001 · doi-reference

Increased thyroidal activity on routine FDG-PET/CT after combination immune checkpoint inhibition: Temporal associations with clinical and biochemical thyroiditis

10.3390/cancers15245803 · doi-reference

Immune checkpoint inhibitors-induced endocrinopathies: Assessment, management and monitoring in a comprehensive cancer centre

10.1002/edm2.505 · doi-reference

Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction

10.1111/1759-7714.13347 · doi-reference

Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis

10.1007/s00262-021-03128-7 · doi-reference

Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis

10.1001/jamaoncol.2017.3064 · doi-reference

Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: A prospective study from a single tertiary center

10.1530/erc-24-0101 · doi-reference

Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study

10.1007/s40618-023-02268-0 · doi-reference